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Anthelmintic resistance (AR) to Fasciola hepatica is emerging worldwide. Recently, AR to the adulticide
compound albendazole (ABZ) was shown in Argentina and Spain. In Sweden, ABZ treatment failure
against F. hepatica was ﬁrst reported in sheep in 2012. The present study tested the efﬁcacy of ABZ and
triclabendazole (TCBZ) in sheep naturally infected with F. hepatica using a combination of three different
diagnostic methods: faecal egg counts (FEC), coproantigen ELISA (cELISA) and Fasciola egg hatch test
(FEHT). Two deworming trials, in November 2014 and January 2015, were performed on two sheep farms
(farms A and B) in south-western Sweden. Except ABZ in November, treatment with ABZ or TCBZ ach-
ieved sufﬁcient efﬁcacy (97e100%) against adult F. hepatica on farm A. In contrast, ABZ treatment failed
in the sheep ﬂock on farm B, despite low initial faecal egg output. On farm B, ABZ efﬁcacy based on FEC
was 67% (95% CI: 35e84) and four of eight ewes tested were coproantigen-positive 21 days post-
treatment. Ovicidal activity of ABZ against Fasciola eggs in isolates from both farms and one additional
bovine isolate were tested by FEHT to exclude the presence of juvenile ﬂukes and other factors such as
dosing failure and poor quality of drug product. Irrespective of drug trial, data from FEHT showed
signiﬁcantly lower ovicidal activity of ABZ for the ovine farm B isolate than for the isolate from farm A.
This conﬁrms that the low efﬁcacy of ABZ in sheep ﬂock B was associated with ABZ resistance. Overall,
the usefulness of three complementary methods for detection of ABZ resistance in the ﬁeld was
demonstrated.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The common liver ﬂuke (Fasciola hepatica) causes signiﬁcant
production disease in sheep and cattle worldwide. Control of fas-
ciolosis is based on treatment with ﬂukicides that differ in chemical
structure and mode of action, but also in their efﬁcacy against
different liver ﬂuke developmental stages (Fairweather and Boray,
1999). Triclabendazole (TCBZ) and albendazole (ABZ) are common
benzimidazoles used against liver ﬂuke infection (Skuce and
Zadoks, 2013). TCBZ is effective against both adult and juvenile
ﬂukes from the age of 2 days, and is the drug of choice for both
sheep and cattle, whereas ABZ is effective only against adult ﬂukes
(from 12 weeks) (Fairweather and Boray, 1999). A demonstratedultural Sciences, Department
Section for Parasitology, Box
ilský).
r Ltd on behalf of Australian Socieminimal inhibition concentration of ABZ for all animal products
and a short withdrawal period for milk (60 h) (Power et al., 2013)
make ABZ one of the most useful ﬂukicides for dairy cattle.
Resistance of liver ﬂukes to ﬂukicides had not been noted until
the ﬁrst report of TCBZ resistance in Australia in 1995 (Overend and
Bowen, 1995). Since then, numerous cases of TCBZ resistance have
been reported in Australia (Brockwell et al., 2014), Europe (Moll
et al., 2000; Daniel et al., 2012; Gordon et al., 2012a; Hanna et al.,
2015) and South America (Olaechea et al., 2011). The signiﬁcant
increase in reported TCBZ resistance has raised new issues
regarding evaluation of ﬂukicide efﬁcacy, diagnostic methods for
anthelmintic resistance (AR) and their interpretation. There is no
standard recommended protocol for determination of ﬂukicide
efﬁcacy/resistance (Fairweather, 2011b; Fairweather et al., 2012).
Faecal egg count reduction test (FECRT) (Coles et al., 2000; Moll
et al., 2000; Hanna et al., 2015), coproantigen reduction test (CRT)
(Flanagan et al., 2011a, 2011b; Brockwell et al., 2013), detection of
ﬂuke DNA in faeces by polymerase chain reaction (PCR) (Robles-
Perez et al., 2013), post-mortem ﬂuke counts (Coles and Stafford,ty for Parasitology. This is an open access article under the CC BY license (http://
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have all been used for detection of ﬂukicide efﬁcacy in ruminants.
In common veterinary practice, a combination of FECRT and CRT
seems to be the most promising methods for detection (Gordon
et al., 2012b; Novobilský et al., 2012; Brockwell et al., 2014; Elliott
et al., 2015; Novobilský and H€oglund, 2015). For most methods,
however, speciﬁc thresholds have not yet been determined, which
makes interpretation problematic, in particular as drug evaluation
can be affected by several other factors such as incorrect dosing,
metabolism status of animals treated, inferior quality of the ﬂuki-
cide product used and/or timing of the drug efﬁcacy trial
(Fairweather, 2011a). Altogether, this makes diagnosis of ﬂukicide
resistance complicated.
In vitro screening of AR is used for some gastrointestinal nem-
atodes, but its application is limited for liver ﬂukes. No reliable
molecular markers for TCBZ resistance have so far been reported
(Elliott and Spithill, 2014; Hodgkinson et al., 2013). However, in
parallel with larval in vitro testing in nematodes, the Fasciola egg
hatch test (FEHT) has been developed to diagnose susceptibility of
F. hepatica eggs to ABZ (Alvarez et al., 2009; Canevari et al., 2014;
Robles-Perez et al., 2014) and TCBZ (Fairweather et al., 2012;
Robles-Perez et al., 2015).
In Sweden, control of bovine and ovine fasciolosis has been
based solely on ABZ for decades (Novobilský et al., 2012, 2015b).
Failure of ABZ treatment in sheep has been reported on a single
farm in south-western Sweden (Novobilský et al., 2012). However,
the exact reasons for this ABZ failure remain unknown. The pres-
ence of juvenile ﬂukes that are unaffected by ABZ makes diagnosis
of adulticide efﬁcacy impractical, especially in cases where animals
are kept outdoors all year round. Implementation of FEHT, which is
independent of drug trial data, metabolism and re-infection status
of animals tested, would improve diagnosis of resistance to adul-
ticide anthelmintics such as ABZ. The aim of the present study was
thus to evaluate ABZ and TCBZ efﬁcacy in sheep naturally infected
with F. hepatica using a combination of faecal egg counts (FEC) and
coproantigen reduction, supported by FEHT. In addition, the effect
of drug application timing was assessed.
2. Material and methods
2.1. Animals
Two ﬂocks of Gotlandic Pelt sheep on islands of south-western
Sweden with a long history of fasciolosis were selected for the
study. Both farms are located off the west coast, north of Gothen-
burg, in a highly liver ﬂuke abundant area (Novobilský et al., 2015a).
One farm (farm A) is located on the island of Orust and the other
(farm B) on the neighbouring island of Tj€orn. The sheep ﬂocks
consist of 70 and 150 ewes on farm A and B, respectively. The dis-
tance between the farms is approx. 30 km, so the climatic condi-
tions are almost identical at both locations. To control liver ﬂuke,
albendazole (ABZ) or/and triclabendazole (TCBZ) have been applied
orally in both sheep ﬂocks for a period of 10 years and 2 years,
respectively. Animals were last treated (with ABZ) 12 months
before the study. In order to select animals with patent liver ﬂuke
infection, 50% of the ewes in each ﬂock were sampled in October
2014. In this pre-screening test, faecal samples were collected and
examined for the presence of F. hepatica coproantigen as described
below. Based on the results of pre-screening, coproantigen-positive
ewes were randomly divided into groups of 6e8 animals.
2.2. Deworming and evaluation of drug efﬁcacy
On both farms, two groups of 6e8 ewes were treated with ABZ
or TCBZ in January (9 and 11 weeks after housing on farm A and B,respectively). To compare the efﬁcacy of ABZ between autumn and
winter deworming, other two groups of ewes were treated with
ABZ or TCBZ on farm A in November (4 weeks after housing).
However, November deworming was not feasible on Farm B, as the
ewes were already pregnant at that time and the use of ABZ is
contraindicated in such cases. All animals were weighed and
treated orally with a commercial formulation of either ABZ (Val-
bazen®, Pﬁzer) at a dose of 7.6 mg per kg bodyweight or TCBZ
(Triclafas® Oral Drench, Norbrook) at a dose of 10 mg per kg
bodyweight. The drug was administered in 50 ml syringes with
0.2 ml accuracy by a licensed veterinary surgeon (employed by
Farm & Animal Health, Sweden) as part of routine deworming. No
ethical permission was required according to the Animal Welfare
Act 2009/021. All drugs were stored in a cool, dry place until use.
The animals were kept indoors during the entire study.
2.3. Faecal egg counts and coproantigen ELISA
Faecal samples were collected on days 0, 7 and 21 post-
treatment, based on previous studies (Moll et al., 2000; Brockwell
et al., 2014; Hanna et al., 2015). The samples were labelled with
the animal ID on ear tags and immediately sent by mail to our
laboratory in Uppsala. The samples were stored at 4 C during de-
livery and storage and processed immediately after arrival. The
maximum interval between sampling on the farm and sample
processing in the laboratory was 48 h. The FEC were conducted by
the sedimentation method on 3 g of faeces as described by
Novobilský and H€oglund (2015). Coproantigen in faecal samples
was determined using a commercial kit BIO-X ELISA (BIO K 201,
BIO-X Diagnostics, Belgium) according to the manufacturer’s pro-
tocol, where coproantigen levels are expressed as a percentage of
positivity of optical density of sample versus optical density of a
positive reference sample. The cut-off value for cELISA was opti-
mised by previous examination of truly F. hepatica-positive and
-negative sheep faecal samples (Brockwell et al., 2013; Novobilský
and H€oglund, 2015). Reference positive sheep faecal samples orig-
inated from previous studies (Novobilský et al., 2012, 2014) where
infection status was conﬁrmed by coproscopy, serology and liver
ﬂuke burden. Negative sheep samples came from F. hepatica-free
herds in Uppsala.
2.4. In vitro Fasciola egg hatch test
Sensitivity of the two ovine F. hepatica isolates to ABZ was
assessed by in vitro FEHT. The principles of FEHT have been
described elsewhere (Alvarez et al., 2009; Fairweather et al., 2012;
Canevari et al., 2014), although our protocol was somewhat modi-
ﬁed as described below. Eggs were obtained from pooled faecal
samples before treatment in both herds (farms A and B). An addi-
tional cattle F. hepatica isolate was obtained from adult worms
collected at a local abattoir (Varekils Slakteri, Lundby) from the liver
of beef cattle from farm C, located approximately 5 km from sheep
farm B.
The FEHT was carried out in 24-well, ﬂat-bottomed plastic
plates (Nunc, Sigma-Aldrich, Sweden). Albendazole powder
(Sigma-Aldrich, Sweden; product ID A4673) was dissolved in
maximum 0.5% dimethyl sulphoxide (DMSO) (Sigma Aldrich,
Sweden, product ID 472301). This maximum concentration of
DMSO had no effect on egg development in our preliminary tests
(Amaya-Solis, 2012) or in a previous study (Fairweather et al.,
2012). Fluke eggs were exposed to ABZ at a ﬁnal concentration of
0.02, 0.1, 0.5, 2.5, 12.5 nmol/ml and 0.5% DMSO only (negative
control) for 12 h at 25 C. Each concentration was tested in four
replicates containing approximately 100 eggs per well. After
exposure, the eggs were washed three times in tap water and then
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the dark. After incubation, miracidial hatching was stimulated by
exposure to intensive light for 12 h. Hatching was terminated by
adding of 0.1 ml Lugol’s iodine solution to each well 4 h after
exposure to light. Hatched and unhatched, including dead eggs and
eggs with developed miracidia were counted under an inverted
microscope at 40x magniﬁcation. Ovicidal activity of ABZ was
calculated according to the formula, below: Ovicidal activity (%) ¼
(% of eggs hatched in negative control - % eggs hatched after drug
exposure/% of eggs hatched in negative control)*100 (Alvarez et al.,
2009; Canevari et al., 2014).
2.5. Statistical analysis
Faecal egg count was calculated by two independent methods.
First, FEC reduction was expressed as a comparison of arithmetic
means between pre-treatment and post-treatment levels with 95%
conﬁdence limit, as recommended by TheWorld Association for the
Advancement of Veterinary Parasitology (WAAVP) (Coles et al.,
1992). In the second method, the percentage of FEC reduction
was obtained using the online Bayesian hierarchical modelling
platform “eggCounts” http://www.math.uzh.ch/as/index.php?
id¼254 (Torgerson et al., 2014).
The cut-off value for coproantigen ELISA was calculated using
receiver operating characteristic (ROC) analysis. Treatment effect
between drugs and also between deworming periods in each herd
was assessed by two-way ANOVA, followed by Bonferroni post-
tests with signiﬁcance P < 0.05. One-way analysis of variance
(ANOVA) was applied to evaluate differences between pre-
treatment and post-treatment FEC and coproantigen levels in
each group. In FEHT, ABZ concentration was plotted against per-
centage of ovicidal activity after probit transformation. A non-
linear regression model was then built to ﬁt dose-response data
from FEHT. The EC50 values, 95% conﬁdence intervals and R2 values
were calculated for each F. hepatica isolate. All analyses were con-
ducted using Graph Pad Prism 5.02 (GraphPad Software, USA).
3. Results
The cut-off value for coproantigen ELISA based on 40 positive
and 40 negative control samples was 1.6% positivity. TCBZ was
highly efﬁcient (FECR 97e100%) in both ﬂocks, irrespective of
deworming period, as documented by FEC and coproantigen levels
(Fig. 1, Tables 1 and 2). On farm A, ABZ efﬁcacy based on FEC (21
days post-treatment) was slightly lower for November treatment
(92%) than for January treatment (99%), but this difference was not
signiﬁcant. FECR values were lower on day 7 in both ABZ and TCBZ
groups and raised to 99% on day 21 post-treatment (Table 2) onFig. 1. Mean coproantigen values for sheep treated with albendazole (ABZ, 7.6 mg/kg) and tr
obtained at days 0, 7 and 21 days post-treatment for deworming in November 2014 and Janu
signiﬁcant difference (*P < 0.05; **P < 0.01) between pre-treatment and post-treatment timfarm A likely due to continuous release of eggs remaining in bile
ducts and gall bladder. Coproantigen efﬁcacy of ABZ was similar in
both the November and January treatments on day 21 post-
treatment. In addition, no signiﬁcant difference in FEC and cop-
roantigen (P > 0.05) was observed between November and January
treatment for the TCBZ and ABZ groups on farm A. On farm B, both
coproantigen and FEC data showed low efﬁcacy in the ABZ group,
where 50% of animals remained coproantigen-positive 21 days
post-treatment (Tables 1 and 2, Fig. 1).
The FEHT data showed an obvious difference in sensitivity to
ABZ between F. hepatica eggs isolated from animals on farms A and
B. At a concentration of 2.5 nmol/ml, the ovicidal activity of ABZ
was 100% for the ovine isolate from farm A but only 54% for the
farm B isolate. Furthermore, the bovine isolate from farm C dis-
played similar poor ovicidal activity to the ovine isolate from farm
B. The EC50 values for the ovine and bovine isolates from farms B
and C were approximately 10-fold higher than that obtained for the
ovine isolate from farm A. Data from FEHT, including EC50 and R2
values, are summarised in Table 3 and Fig. 2.
4. Discussion
It has been suggested that ABZ resistance may be present in F.
hepatica in Swedish sheep ﬂocks in response to long term use of
lower doses (e.g. 5 mg/kg bodyweight) than the recommended
(7.5 mg/kg) in most countries (Novobilský et al., 2012). However,
until now, convincing evidence for this claim has been lacking. In
the present study, both reduced efﬁcacy and decreased sensitivity
of ﬂuke eggs to ABZ was conﬁrmed in a F. hepatica population from
one sheep ﬂock on the Swedish west coast using two independent
coprological methods and an in vitro egg hatch test, respectively.
ABZ resistance is difﬁcult to prove in the ﬁeld due to the potential
presence of juvenile ﬂukes, which are tolerant to the drug and thus
unaffected by treatment. However, as the results of the in vitro test
conﬁrmed the outcome from the ﬁeld trial, the observed ABZ
treatment failure was most likely associated with resistance.
When ﬂukicides are applied in general practice, diagnosis of
ﬂukicide efﬁcacy/resistance can be compromised by several factors.
For example, underdosing, poor quality of anthelmintic product,
age of product, changes in drug metabolism within animals, inap-
propriate diagnostic tests may often be misdiagnosed as AR
(Fairweather, 2011a; Skuce and Zadoks, 2013). In addition, in the
case of adulticide drugs, misinterpretation related to the develop-
ment of juvenile ﬂukes surviving treatment must always be
considered (Coles et al., 2006). TheWAAVP guidelines cite dose and
slaughter trials as the only deﬁnitive method for detection of AR
(Coles et al., 2006). However, this involves costly and lengthy
experimental infection of cultured snails and maintenance oficlabendazole (TCBZ, 10 mg/kg) on farm A (Orust) and farm B (Tj€orn), in faecal samples
ary 2015. Coproantigen values are expressed as % of positivity. Abbreviations: *Indicates
e interval. n.s. ¼ not signiﬁcant.
Table 1
Summary of faecal egg counts (FEC) expressed as eggs per gram faeces (EPG) and coproantigen level (% positivity) measured on sheep farms on farm A (Orust) and farm B
(Tj€orn).
Farm A Farm B
November January January




n.a. 56.0 ± 44.1 0.7 ± 1.2 4.6 ± 10.5 n.a. 135.5 ± 153.0 60.3 ± 131.4 1.8 ± 4.5 n.a. 3.9 ± 4.6 1.1 ± 2.2 1.2 ± 1.4
Number of F. hepatica
egg shedding animals
(number of animals in
the group)




41.9 ± 34.9 29.1 ± 27.8 1.0 ± 1.2 0.8 ± 0.6 29.0 ± 25.8 31.2 ± 30.2 1.5 ± 3.6 0.6 ± 0.8 8.1 ± 9.0 5.3 ± 5.0 1.3 ± 1.2 3.6 ± 4.3
Number of coproantigen
positive animals
(number of animals in
the group)




n.a. 72.8 ± 71.2 13.4 ± 30.8 0.1 ± 0.1 n.a. 62.9 ± 76.7 9.6 ± 14.3 0.4 ± 0.3 n.a. 3.1 ± 2.1 0.0 0.0
Number of F. hepatica
egg shedding animals
(number of animals in
the group)




36.5 ± 27.7 24.7 ± 20.8 0.3 ± 0.2 0.5 ± 0.3 37.8 ± 25.6 25.5 ± 25.7 0.1 ± 0.8 0.3 ± 0.4 7.8 ± 7.8 8.2 ± 7.6 0.1 ± 0.5 0.3 ± 0.3
Number of coproantigen
positive animals
(number of animals in
the group)
8 (8) 8 (8) 0 (8) 0 (8) 6 (7)a 7 (7) 0 (7) 0 (7) 7 (7) 6 (7) 0 (7) 0 (7)
Abbreviations:ABZ ¼ albendazole, TCBZ ¼ triclabendazole.
a On farm A in January, 2 and 1 sheep were slaughtered in period between pre-screening (Day -75) and Day 0 in ABZ and TCBZ group, respectively. These slaughtered
animals were replaced with 3 other coproantigen and Fasciola hepatica egg positive sheep on Day 0. Data for these 3 slaughtered sheep were not included on Day -75.
Table 2
Efﬁcacy of albendazole and triclabendazole against liver ﬂukes based on faecal egg counts (FEC) and coproantigen ELISA tests on faecal samples obtained 7 and 21 days post-
treatment on sheep farms on Orust (farm A) and Tj€orn (farm B).
Farm A Farm B
November January January
Day 7 Day 21 Day 7 Day 21 Day 7 Day 21
Albendazole FECR in %, (95% CI)a 99 (94e100) 92 (35e99) 56 (0e93) 99 (90e100) 71 (0e95) 69 (0e91)
FECR in %, (95% CI)b 99 (97e100) 92 (88e94) 56 (51e60) 99 (98e99) 73 (45e88) 67 (35e84)
Coproantigen reduction in % 97 97 95 98 76 32
Triclabendazole FECR in %, (95% CI)a 82 (0e97) 100 85 (30e97) 99 (94e100) 100 100
FECR in %, (95% CI)b 82 (77e85) 100 (99e100) 85 (80e88) 99 (98e100) 97 (82e100) 97 (83e100)
Coproantigen reduction in % 99 98 100 99 99 97
Abbreviations: 95% CI ¼ 95% conﬁdence interval, FECR ¼ faecal egg count reduction.
a Faecal egg count reduction calculated according to Coles et al. (1992).
b Faecal egg count reduction calculated according to Torgerson et al. (2014).
Table 3
Ovicidal efﬁcacy determined by in vitro Fasciola egg hatch test (FEHT) of albendazole (ABZ) at concentrations 0.02, 0.1, 0.5, 2.5, and 12.5 nmol/ml against F. hepatica eggs of two
ovine isolates (farm A and B) and one bovine isolate (farm C).
ABZ (nmol/ml) Ovicidal efﬁcacy
Ovine isolate (Farm A) Ovine isolate (Farm B) Bovine isolate (Farm C)
12.5 100 100 100
2.5 100 54.5 74.2
0.5 94.4 37.5 22.2
0.1 57.2 20.9 6.1
0.02 3.6 16.4 5.8
EC50 0.087 0.947 1.171
95% CI of EC50 0.078 to 0.098 0.207 to 4.334 0.822 to 1.667
R2 0.998 0.901 0.993
Abbreviations:; EC50 ¼ effective concentration for 50% inhibition; R2 ¼ coefﬁcient in regression analysis.
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Fig. 2. Dose-response curves of albendazole (ABZ) ovicidal activity for ovine (farms A
and B) and bovine (farm C) Fasciola hepatica egg isolates after probit transformation of
ABZ concentrations.
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kicide resistance provides a new approach that is independent of
drug efﬁcacy trials in treated animals. In the present study, we
observed ABZ failure on farm B, as documented by FEC (67% efﬁ-
cacy) and coproantigen (32% efﬁcacy) (Table 2). However, it should
be emphasised that ABZ was applied in the beginning of January,
exactly 9 weeks after housing on this farm. Thus, presence of ju-
venile ﬂukes cannot be completely excluded on farm B and a
decreasing trend in efﬁcacy of both FEC and coproantigen (Table 2)
could hypothetically indicate maturation of juvenile ﬂukes surviv-
ing treatment. Furthermore, both initial FEC and coproantigen
levels were very low, suggesting a modest ﬂuke burden. In nema-
todes, low initial FEC before treatment decreases the reliability of
FECRT (Coles et al., 1992). It can be assumed that a similar pattern
applies for FEC and coproantigen in F. hepatica. Thus, decisions
about the resistance status of the ovine F. hepatica population on
farm B cannot be completely conclusive based only on the FECR and
cELISA results. On the other hand, signiﬁcant differences in ovicidal
activity in FEHT between the ovine isolates studied here conﬁrmed
that the isolate from farm B possessed signiﬁcantly lower suscep-
tibility to ABZ than the isolate from farm A. Obvious differences
between the isolates studied were also observed in terms of ABZ
efﬁcacy based on FEC and cELISA. Thus, the F. hepatica isolate from
farm B is most likely resistant to ABZ.
The majority of studies dealing with ﬂukicide resistance focus
on the most effective drug, TCBZ, which is effective against both
juvenile and adult ﬂukes in livestock (see review by Fairweather,
2011b). In contrast, diagnosis of ABZ susceptibility/resistance has
been neglected. So far, the only experimentally conﬁrmed pub-
lished account of a “dose and slaughter trial” ABZ-resistant ﬂuke
population is in Argentina (Sanabria et al., 2013). Field-based cases
of ABZ resistance have been reported in Spain and Egypt (Alvarez-
Sanchez et al., 2006; Robles-Perez et al., 2013; Shokier et al., 2013;
Martinez-Valladares et al., 2014). In addition, the Argentinian
CEDIVE isolate (Sanabria et al., 2013) and the Spanish Santillan de la
Vega isolate (Robles-Perez et al., 2013) have been conﬁrmed as
ABZ-resistant by in vitro FEHT (Canevari et al., 2014; Robles-Perez
et al., 2014). However, reports of ﬁeld-documented ﬂukicide
resistance that subsequently turn out as incorrect by further
investigation have also been presented (Fairweather, 2011b). This
shows that combining ﬁeld drug trials with in vitro FEHT is
necessary for correct diagnosis of ABZ resistance. Interestingly, ABZ
is effective in TCBZ-resistant populations (Coles and Stafford, 2001)
despite both actives being benzimidazole derivates. At the same
time sheep with ABZ-resistant ﬂukes have been successfully
treated with TCBZ (Robles-Perez et al., 2013; Sanabria et al., 2013),as also documented in our study. This clearly supports the theory
that the molecular mechanisms of ABZ and TCBZ resistance differ.
Underdosing, long-term use of compounds with the same mode
of action and high frequency of treatment are key factors in
development of AR in gastrointestinal nematodes (Kaplan, 2004).
In Sweden, ABZ has been used against liver ﬂukes for decades, as
until recently it was the only licensed ﬂukicide. However, the dose
used for deworming is 1.5-fold lower than recommended in several
other countries (Novobilský et al., 2012). Therefore, the recom-
mended dose of Valbazen (ABZ) in Sweden was recently increased
to 7.6 mg/kg of ABZ, i.e. the dose that was used in this study.
Repeated underdosing and long-term use of ABZ only might
explain the emergence of ABZ resistance in Sweden.
Albendazole acts only against mature ﬂukes older than 12
weeks post-infection (Johns and Dickeson,1979; Coles and Stafford,
2001). Thus, ABZ is not usually effective when applied during or
immediately after the grazing season, due to the presence of
immature ﬂukes (Mitchell, 2002). Surprisingly, the ﬁnal effect of
drug application timing between November and January
deworming in this study did not differ for either drug on farm A.
Although FECR for ABZ was slightly lower in November, cop-
roantigen values did not differ from the January results. In the
autumn treatment, the drugs were applied 4 weeks after housing.
Although immature ﬂukes could be expected in ewes at that time of
the year, ABZ efﬁcacy was similar to that observed at the January
treatment suggesting that all ﬂukes were mature already in
November. In Sweden, sheep are infected at the earliest in
MayeJunewithmetacercarial cysts shed from overwintering snails,
but also in JulyeAugust as a result of summer infection (Novobilský
et al., 2014). Thus, sheep on farm A were most likely infected in
early summer and, from a practical point of view, our results
indicate that treatment with ABZ could be applied from November
onwards during the housing period.
The FEHT is a relatively new in vitro method for testing the
ovicidal activity of ﬂukicides. In this study, we used short-term
exposure (12 h) to ABZ according to Alvarez et al. (2009), as this
time corresponds to in vivo exposure. In other studies (Fairweather
et al., 2012; Robles-Perez et al., 2014, 2015), Fasciola eggs were
incubated for 14 days until hatching of miracidia. Using DMSO at a
ﬁnal concentration of 0.5% in our protocol did not affect the
viability of the eggs. This concentration was suggested by our
preliminary testing (Amaya-Solis, 2012), and by a previous in vitro
studywith TCBZ (Fairweather et al., 2012). Higher concentrations of
DMSO seem to have an ovicidal effect in F. hepatica.
In FEHT optimisation, the highest variation in the ovicidal ac-
tivity of ABZ was observed in the range 0.1e2.5 nmol/ml (Amaya-
Solis, 2012). Similarly, Canevari et al. (2014) showed that
0.5 nmol/ml is the threshold ABZ concentration to discriminate
between ABZ-resistant and ABZ-susceptible F. hepatica isolates. At
this ABZ concentration, ovicidal efﬁcacy of 40% or 70% indicates
resistance and susceptibility to ABZ, respectively. We observed
ovicidal efﬁcacy of 94% (farm A), 22% (farm B) and 37% (farm C),
suggesting that the ovine and bovine isolates from two nearby
farms (B and C, respectively) were most likely ABZ-resistant. In
nematodes, susceptibility/resistance status of isolates in in vitro
tests is compared strictly on a dose-response basis using linear or
non-linear regression and comparison of data against a standard
resistant reference strain (Taylor et al., 2002; Demeler et al., 2010).
In this study, F. hepatica isolates were exposed to ABZ concentra-
tions in the range 0.02e12.5 nmol/ml and there was a noticeable
dose-response effect. High R2 values (R2 > 0.9 for all three isolates)
in non-linear regression showed that the model ﬁtted our data.
Since no standard ABZ-resistant reference F. hepatica isolate is
available, interpretation of FEHT data is difﬁcult. However, the EC50
value of the ovine isolate from farm A was 10-fold lower than that
A. Novobilský et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 141e147146obtained for the ovine (farm B) and bovine (farm C) isolates from
Tj€orn, suggesting signiﬁcant differences in their susceptibility to
ABZ.
5. Conclusions
Albendazole is a commonly used ﬂukicide around the world.
Unlike in many other European countries it has long been used as
drug of ﬁrst choice against liver ﬂukes in sheep in Sweden. The ﬁrst
conﬁrmed case of ABZ resistance in sheep in Sweden is reported in
this study. This ﬁnding should be taken into account in future
planning of control strategies against fasciolosis. Combined testing
with FEC, cELISA and FEHT appears to be efﬁcient in diagnosis of
ABZ resistance in the ﬁeld. Despite high efﬁcacy of ABZ at
November deworming observed in the study, we recommend using
ABZ at least 12 weeks after housing in sheep, since time of ﬂuke
infection may vary between locations. In addition, ABZ is contra-
indicated in the ﬁrst 30 days of gestation.
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